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Abstract
© Schattauer 2015. The role of anticoagulants and antiplatelet agents in tumour growth and
prognosis is not new, and currently under intense investigation. Some randomised data strongly
suggest that this association exists, but it is complex, and not necessarily pointed at the same
direction. The potential mechanisms responsible for such harmful association include a direct
hazard  of  novel  antithrombotics  on  cancer,  indirect  promotion  of  tumour  growth,  easier
metastatic dissemination due to instability of platelet-tumour cell aggregates, or/and inability to
keep cancer cells locally in situ are considered. The latest randomised evidence ultimately
rejected the drug-specific cancer risks, clearly indicating the class-effect. In lay terms “cancers
follow bleeding”, which seems to be true for antithrombotic agents in general. Significant excess
of solid cancers which was similar after prasugrel in TRITON, and with vorapaxar in TRACER
trials  was  confirmed  by  the  FDA  reviews.  Later,  extra  cancer  deaths  reported  following
clopidogrel  and  prasugrel  in  DAPT,  and  after  ticagrelor  in  PEGASUS  are  also  of  concern.
However,  there  are  remaining  controversies  with  regard  to  published  cancer  risks  after
ticagrelor  (PLATO),  or  another  vorapaxar  trial  (TRA2P),  while  full  disclosure  of  separate
clopidogrel and prasugrel cancer data in DAPT is still lacking. In short, if we apply moderate
antiplatelet strategies for over two years, or aggressive regimens including triple therapy for
much less than one year,  the solid cancer risks emerge.  Currently,  more delicate platelet
inhibition, and shorter exposure to dual oral antiplatelet agents should prevail.
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